Advertisement

Psychopharmacology

, Volume 205, Issue 4, pp 589–597 | Cite as

Effects of the H3 antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats

  • Mark E. BardgettEmail author
  • Megan Points
  • John Roflow
  • Meredith Blankenship
  • Molly S. Griffith
Original Investigation

Abstract

Rationale

Recent studies have raised the possibility that antagonists of H3 histamine receptors possess cognitive-enhancing and antipsychotic properties. However, little work has assessed these compounds in classic animal models of schizophrenia.

Objectives

The purpose of this study was to determine if a prototypical H3 antagonist, thioperamide, could alter behavioral deficits caused by the N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801, in adult male rats. MK-801 was chosen to be studied since it produces a state of NMDA receptor hypofunction in rats that may be analogous to the one hypothesized to occur in schizophrenia.

Methods

The interaction between thioperamide and MK-801 was measured in three behavioral tests: locomotor activity, prepulse inhibition (PPI), and delayed spatial alternation. In each test, rats received a subcutaneous injection of saline or thioperamide (3.0 and 10 mg/kg) followed 20 min later by a subcutaneous injection of saline or MK-801 (0.05, 0.10, and 0.30 mg/kg).

Results

Locomotor activity was significantly elevated by MK-801 in a dose-dependent manner. Thioperamide pretreatment alone did not alter locomotor activity; however, its impact on MK-801 was dose-dependent. Each thioperamide dose enhanced the effects of two lower doses of MK-801 but reduced the effect of a higher MK-801 dose. Clear deficits in PPI and delayed spatial alternation were produced by MK-801 treatment, but neither impairment was significantly modified by thioperamide pretreatment.

Conclusions

H3 receptors modulate responses to NMDA antagonists in behaviorally specific and dose-dependent ways.

Keywords

Antipsychotic Cognition Locomotor activity Prepulse inhibition Spatial working memory NMDA receptor 

Notes

Acknowledgments

This research was supported by the National Center for Research Resources Grant P20 RR16481 and National Institute of Mental Health Grant R15 MH076788. We would like to acknowledge the NIMH Chemical Synthesis and Drug Supply Program providing the thioperamide used in this study. The experiments reported here comply with Current Guide for the Care and Use of Laboratory Animals (USPHS) and were performed under a protocol approved by the Northern Kentucky University Institutional Animal Use and Care Committee.

References

  1. Bakshi VP, Geyer MA (1998) Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18:8394–8401PubMedGoogle Scholar
  2. Bardgett ME (2004) Behavioral models of atypical antipsychotic drug action. In: Csernansky JG, Laurello J (eds) Atypical antipsychotics: from bench to bedside. Marcel Dekker, New York, pp 61–93Google Scholar
  3. Bardgett ME, Jacobs PS, Jackson JL, Csernansky JG (1997) Kainic acid lesions enhance locomotor responses to novelty, saline, amphetamine, and MK-801. Behav Brain Res 87:47–55CrossRefGoogle Scholar
  4. Bardgett ME, Griffith MS, Foltz RF, Hopkins JA, Massie CM, O’Connell SM (2006a) The effects of clozapine on delayed spatial alternation in rats with hippocampal damage. Neurobiol Learn Mem 85:86–94PubMedCrossRefGoogle Scholar
  5. Bardgett ME, Hon JG, Lee NM, O’Connell SM, Baum KM (2006b) Effects of risperidone on locomotor activity and spatial memory in rats with hippocampal damage. Neuropharmacology 51:1156–1162PubMedCrossRefGoogle Scholar
  6. Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, Lamontagne T, Griffith MS (2008) The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology 33:1980–1991PubMedCrossRefGoogle Scholar
  7. Bernaerts P, Lamberty Y, Tirelli E (2004) Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behav Brain Res 154:211–219PubMedCrossRefGoogle Scholar
  8. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, Pepeu G, Giovannini MG (1996) Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 119:1656–1664PubMedGoogle Scholar
  9. Brabant C, Alleva L, Grisar T, Quertemont E, Lakaye B, Ohtsu H, Lin JS, Jatlow P, Picciotto MR, Tirelli E (2009) Effects of the H(3) receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology 202:673–687PubMedCrossRefGoogle Scholar
  10. Brosnan-Watters G, Wozniak DF, Nardi A, Olney JW (1996) Acute behavioral effects of MK-801 in the mouse. Pharmacol Biochem Behav 53:701–711PubMedCrossRefGoogle Scholar
  11. Brown RE, Haas HL (1999) On the mechanism of histaminergic inhibition of glutamate release in the rat dentate gyrus. J Physiol 515:777–786PubMedCrossRefGoogle Scholar
  12. Browman KE, Komater VA, Curzon P, Rueter LE, Hancock AA, Decker MW, Fox GB (2004) Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res 153:69–76PubMedCrossRefGoogle Scholar
  13. Clapham J, Kilpatrick GJ (1992) Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 107:919–923PubMedGoogle Scholar
  14. Clapham J, Kilpatrick GJ (1994) Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259:107–114PubMedCrossRefGoogle Scholar
  15. Dai H, Zhang Z, Zhu Y, Shen Y, Hu W, Huang Y, Luo J, Timmerman H, Leurs R, Chen Z (2006) Histamine protects against NMDA-induced necrosis in cultured cortical neurons through H receptor/cyclic AMP/protein kinase A and H receptor/GABA release pathways. J Neurochem 96:1390–1400PubMedCrossRefGoogle Scholar
  16. Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007) The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 563:117–123PubMedCrossRefGoogle Scholar
  17. Farber NB, Newcomer JW, Olney JW (1998) The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer’s disease. Prog Brain Res 116:421–37PubMedCrossRefGoogle Scholar
  18. Faucard R, Armand V, Héron A, Cochois V, Schwartz JC, Arrang JM (2006) N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem 98:1487–1496PubMedCrossRefGoogle Scholar
  19. Flood JF, Uezu K, Morley JE (1998) Effect of histamine H2 and H3 receptor modulation in the septum on post-training memory processing. Psychopharmacology 140:279–84PubMedCrossRefGoogle Scholar
  20. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA (2003) Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 305:897–908PubMedCrossRefGoogle Scholar
  21. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313:176–190PubMedCrossRefGoogle Scholar
  22. Garduño-Torres B, Treviño M, Gutiérrez R, Arias-Montaño JA (2007) Pre-synaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus. Neuropharmacology 52:527–535PubMedCrossRefGoogle Scholar
  23. Hancock AA (2006) The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem Pharmacol 71:1103–1113PubMedCrossRefGoogle Scholar
  24. Huang YW, Hu WW, Chen Z, Zhang LS, Shen HQ, Timmerman H, Leurs R, Yanai K (2004) Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague–Dawley rats. Behav Brain Res 151:287–293PubMedCrossRefGoogle Scholar
  25. Jacobs PS, Taylor BM, Bardgett ME (2000) Maturation of locomotor and Fos responses to NMDA antagonists, PCP and MK-801. Dev Brain Res 122:91–95CrossRefGoogle Scholar
  26. Komater VA, Buckley MJ, Browman KE, Pan JB, Hancock AA, Decker MW, Fox GB (2005) Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav Brain Res 159:295–300PubMedCrossRefGoogle Scholar
  27. Le S, Gruner JA, Mathiasen JR, Marino MJ, Schaffhauser H (2008) Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 325:902–909PubMedCrossRefGoogle Scholar
  28. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658–666PubMedGoogle Scholar
  29. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC (2007) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 73:1215–1224PubMedCrossRefGoogle Scholar
  30. Mogensen J, Boyd MH, Nielsen MD, Kristensen RS, Malá H (2008) Erythropoietin improves spatial delayed alternation in a T-maze in rats subjected to ablation of the prefrontal cortex. Brain Res Bull 77:1–7PubMedCrossRefGoogle Scholar
  31. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC (1999) Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 288:590–596PubMedGoogle Scholar
  32. Morisset S, Pilon C, Tardivel-Lacombe J, Weinstein D, Rostene W, Betancur C, Sokoloff P, Schwartz JC, Arrang JM (2002) Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J Pharmacol Exp Ther 300:621–628PubMedCrossRefGoogle Scholar
  33. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118PubMedCrossRefGoogle Scholar
  34. Orsetti M, Ghi P, Di Carlo G (2001) Histamine H(3)-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task. Behav Brain Res 124:235–242PubMedCrossRefGoogle Scholar
  35. Perez-Garcia C, Morales L, Cano MV, Sancho I, Alguacil LF (1999) Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology 142:215–220PubMedCrossRefGoogle Scholar
  36. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, Arrang JM (2002) A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 114:173–193PubMedCrossRefGoogle Scholar
  37. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353–359PubMedCrossRefGoogle Scholar
  38. Schwartz JC, Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Arrang JM (2003) Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. J Neural Transm Suppl 64:1–16PubMedGoogle Scholar
  39. Takahata R, Moghaddam B (2003) Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28:1117–1124PubMedGoogle Scholar
  40. Wozniak DF, Olney JW, Kettinger L 3rd, Price M, Miller JP (1990) Behavioral effects of MK-801 in the rat. Psychopharmacology 101:47–56PubMedCrossRefGoogle Scholar
  41. Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE (2005) Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug–drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res 1045:142–149PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Mark E. Bardgett
    • 1
    Email author
  • Megan Points
    • 1
  • John Roflow
    • 1
  • Meredith Blankenship
    • 1
  • Molly S. Griffith
    • 1
  1. 1.Department of PsychologyNorthern Kentucky UniversityHighland HeightsUSA

Personalised recommendations